« Back to Record
Citation APA

Fernandez-Martinez, A., Tanioka, M., Ahn, S.-G., Zagami, P., Pascual, T., Rediti, M., Tang, G., Hoadley, K. A., Venet, D., Rashid, N. U., Spears, P. A., Di Cosimo, S., de Azambuja, E., Choudhury, A., Rastogi, P., Islam, M. N., Cortes, J., Llombart-Cussac, A., Swain, S. M., Sotiriou, C., Prat, A., Perou, C. M., & Carey, L. A. (2024). Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). Annals of oncology. doi:10.1016/j.annonc.2024.12.010


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/387946

Fernandez-Martinez, A., Tanioka, M., Ahn, S.-G., Zagami, P., Pascual, T., Rediti, M., Tang, G., Hoadley, K. A., Venet, D., Rashid, N. U., Spears, P. A., Di Cosimo, S., de Azambuja, E., Choudhury, A., Rastogi, P., Islam, M. N., Cortes, J., Llombart-Cussac, A., Swain, S. M., Sotiriou, C., Prat, A., Perou, C. M., & Carey, L. A. (2024). Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC). Annals of oncology. doi:10.1016/j.annonc.2024.12.010